Clinical Utility of Quantitative MRI Parameters for Differentiation of Renal Tumor Subtypes and Who Grades: A...

Background/Objectives: To evaluate the clinical utility and diagnostic performance of quantitative MRI parameters (T1, T2*, R2*, and ADC) in differentiating renal tumor subtypes and WHO grades, and to assess their potential role in non-invasive tumor characterization. Methods: This retrospective study included 82 patients with histopathologically confirmed renal tumors who underwent preoperative contrast-enhanced MRI between July 2019 and January 2024. Quantitative measurements were obtained from tumor regions and contralateral healthy renal cortex using standardized ROI-based analysis. Parameters included T2*, native and post-contrast T1, R2* (1/T2*), and ADC values. Interobserver agreement was assessed. A Random Forest model was used as a supplementary analytical tool. Results: The cohort included 82 patients (mean age: 59.3 years). Tumors were classified into multiple subtypes, with clear cell carcinoma being the most common (n = 46). High-grade tumors (WHO grades 3-4) demonstrated significantly lower ADC values (p = 0.029) and larger tumor size (p = 0.0017). Significant differences in T2*, R2*, and ADC values were observed across tumor subtypes (p < 0.05). Quantitative MRI parameters demonstrated moderate discriminatory performance, with ADC emerging as the most robust biomarker. The Random Forest model achieved an overall accuracy of 93.2%, primarily driven by ADC and post-contrast T1 values. Conclusions: Quantitative MRI parameters, particularly ADC, provide clinically meaningful non-invasive biomarkers for renal tumor characterization. Their combined interpretation, supported by contralateral renal cortex comparison, may enhance clinical decision-making. Further validation in larger cohorts is warranted.